302 related articles for article (PubMed ID: 23329850)
1. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.
Durbin AP; Kirkpatrick BD; Pierce KK; Elwood D; Larsson CJ; Lindow JC; Tibery C; Sabundayo BP; Shaffer D; Talaat KR; Hynes NA; Wanionek K; Carmolli MP; Luke CJ; Murphy BR; Subbarao K; Whitehead SS
J Infect Dis; 2013 Mar; 207(6):957-65. PubMed ID: 23329850
[TBL] [Abstract][Full Text] [Related]
2. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
[TBL] [Abstract][Full Text] [Related]
3. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.
Kirkpatrick BD; Durbin AP; Pierce KK; Carmolli MP; Tibery CM; Grier PL; Hynes N; Diehl SA; Elwood D; Jarvis AP; Sabundayo BP; Lyon CE; Larsson CJ; Jo M; Lovchik JM; Luke CJ; Walsh MC; Fraser EA; Subbarao K; Whitehead SS
J Infect Dis; 2015 Sep; 212(5):702-10. PubMed ID: 25801652
[TBL] [Abstract][Full Text] [Related]
4. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.
George SL; Wong MA; Dube TJ; Boroughs KL; Stovall JL; Luy BE; Haller AA; Osorio JE; Eggemeyer LM; Irby-Moore S; Frey SE; Huang CY; Stinchcomb DT
J Infect Dis; 2015 Oct; 212(7):1032-41. PubMed ID: 25791116
[TBL] [Abstract][Full Text] [Related]
5. A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.
Durbin AP; Whitehead SS; Shaffer D; Elwood D; Wanionek K; Thumar B; Blaney JE; Murphy BR; Schmidt AC
PLoS Negl Trop Dis; 2011 Aug; 5(8):e1267. PubMed ID: 21829748
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial.
Kallas EG; Precioso AR; Palacios R; Thomé B; Braga PE; Vanni T; Campos LMA; Ferrari L; Mondini G; da Graça Salomão M; da Silva A; Espinola HM; do Prado Santos J; Santos CLS; Timenetsky MDCST; Miraglia JL; Gallina NMF; Weiskopf D; Sette A; Goulart R; Salles RT; Maestri A; Sallum AME; Farhat SCL; Sakita NK; Ferreira JCOA; Silveira CGT; Costa PR; Raw I; Whitehead SS; Durbin AP; Kalil J
Lancet Infect Dis; 2020 Jul; 20(7):839-850. PubMed ID: 32220283
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.
Sun W; Cunningham D; Wasserman SS; Perry J; Putnak JR; Eckels KH; Vaughn DW; Thomas SJ; Kanesa-Thasan N; Innis BL; Edelman R
Hum Vaccin; 2009; 5(1):33-40. PubMed ID: 18670195
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.
Osorio JE; Velez ID; Thomson C; Lopez L; Jimenez A; Haller AA; Silengo S; Scott J; Boroughs KL; Stovall JL; Luy BE; Arguello J; Beatty ME; Santangelo J; Gordon GS; Huang CY; Stinchcomb DT
Lancet Infect Dis; 2014 Sep; 14(9):830-8. PubMed ID: 25087476
[TBL] [Abstract][Full Text] [Related]
9. A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults.
Russell KL; Rupp RE; Morales-Ramirez JO; Diaz-Perez C; Andrews CP; Lee AW; Finn TS; Cox KS; Falk Russell A; Schaller MM; Martin JC; Hyatt DM; Gozlan-Kelner S; Bili A; Coller BG
Hum Vaccin Immunother; 2022 Nov; 18(5):2046960. PubMed ID: 35290152
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study.
Rupp R; Luckasen GJ; Kirstein JL; Osorio JE; Santangelo JD; Raanan M; Smith MK; Wallace D; Gordon GS; Stinchcomb DT
Vaccine; 2015 Nov; 33(46):6351-9. PubMed ID: 26384447
[TBL] [Abstract][Full Text] [Related]
11. Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles.
Lindow JC; Durbin AP; Whitehead SS; Pierce KK; Carmolli MP; Kirkpatrick BD
Vaccine; 2013 Jul; 31(33):3347-52. PubMed ID: 23735680
[TBL] [Abstract][Full Text] [Related]
12. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003.
Tu HA; Nivarthi UK; Graham NR; Eisenhauer P; Delacruz MJ; Pierce KK; Whitehead SS; Boyson JE; Botten JW; Kirkpatrick BD; Durbin AP; deSilva AM; Diehl SA
Cell Rep Med; 2020 Dec; 1(9):100155. PubMed ID: 33377126
[TBL] [Abstract][Full Text] [Related]
14. A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults.
Gunale B; Farinola N; Yeolekar L; Shrivastava S; Girgis H; Poonawalla CS; Dhere RM; Arankalle V; Chandra Mishra A; Mehla R; Kulkarni PS
Vaccine; 2023 Aug; 41(38):5614-5621. PubMed ID: 37532611
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate.
Jackson LA; Rupp R; Papadimitriou A; Wallace D; Raanan M; Moss KJ
Vaccine; 2018 Jun; 36(27):3976-3983. PubMed ID: 29789238
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants.
Watanaveeradej V; Simasathien S; Nisalak A; Endy TP; Jarman RG; Innis BL; Thomas SJ; Gibbons RV; Hengprasert S; Samakoses R; Kerdpanich A; Vaughn DW; Putnak JR; Eckels KH; Barrera Rde L; Mammen MP
Am J Trop Med Hyg; 2011 Aug; 85(2):341-51. PubMed ID: 21813857
[TBL] [Abstract][Full Text] [Related]
17. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?
Whitehead SS
Expert Rev Vaccines; 2016; 15(4):509-17. PubMed ID: 26559731
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.
Kanesa-thasan N; Sun W; Kim-Ahn G; Van Albert S; Putnak JR; King A; Raengsakulsrach B; Christ-Schmidt H; Gilson K; Zahradnik JM; Vaughn DW; Innis BL; Saluzzo JF; Hoke CH
Vaccine; 2001 Apr; 19(23-24):3179-88. PubMed ID: 11312014
[TBL] [Abstract][Full Text] [Related]
19. Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial.
Walsh MR; Alam MS; Pierce KK; Carmolli M; Alam M; Dickson DM; Bak DM; Afreen S; Nazib F; Golam K; Qadri F; Diehl SA; Durbin AP; Whitehead SS; Haque R; Kirkpatrick BD
Lancet Infect Dis; 2024 Feb; 24(2):150-160. PubMed ID: 37776876
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial.
Watanaveeradej V; Gibbons RV; Simasathien S; Nisalak A; Jarman RG; Kerdpanich A; Tournay E; De La Barrerra R; Dessy F; Toussaint JF; Eckels KH; Thomas SJ; Innis BL
Am J Trop Med Hyg; 2014 Jul; 91(1):119-28. PubMed ID: 24865677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
